75A50121C00073 FINAL JA_signed 9-30-2021_Redacted.pdf

This document summarizes a sole source contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The contract was awarded to Elusys Therapeutics, Inc. on January 11, 2022 for an unknown amount. It is for the manufacture of finished drug product Anthim (obiltoxaximab) 600mg/6mL for injection and vendor managed inventory services including rotation and cold-chain distribution of the FDA approved Anthrax antitoxin pharmaceutical Anthim injection. The period of performance is from the date of award through February 25, 2023, including options and option quantities. The contract was awarded in response to COVID-19 and future pandemic preparedness to supply the United States Government's requirement for the Anthrax antitoxin during public health emergencies.